Galectin-1 Reduces the Severity of Herpes Simplex Virus-Induced Ocular Immunopathological Lesions
The Journal of Immunology, 04/23/2012Rajasagi NK et al.
The authors findings are the first to show that galectin–1 (gal–1) treatment represents a useful approach to control lesion severity in a virally induced immunopathological disease.
Barry T. Rouse (05/04/2012)
Controlling chronic immunopathological lesions in the eye such as those caused by ocular herpes simplex virus-1 (HSV) infection remains a major therapeutic challenge. HSV induced stromal keratitis (SK) lesions are thought to be primarily orchestrated by CD4+ T cells of the Th1 subtype with some involvement of Th17 CD4+ T cells. One therapeutic strategy would be to suppress the function of effector CD4+ T cell subsets and the events they orchestrate, as we demonstrate can be achieved by galectin-1 (gal-1) treatment. Our data showed that treatment with recombinant gal-1 significantly diminished SK lesion severity and the extent of corneal neovacularization. The beneficial effect of gal-1 was the consequence of multiple mechanisms. These included apoptotic effects on pro-inflammatory T cells, reduced recruitment of tissue-damaging neutrophils, inhibitory effects on inflammatory cytokine and chemokine production, an increased production of the anti-inflammatory IL-10, as well as an inhibitory effect on the corneal neovascularization needed for inflammatory cells to access the corneal stroma. Our results indicate that gal-1 treatment may represent a useful approach to control HSV-induced ocular lesions, the most common infectious cause of blindness in the western world.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.